First-year cost savings may be greater with etanercept in RA

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1498, 2005-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

First-year cost savings may be greater with etanercept in RA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 482, 2005-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Etanercept of greater value than adalimumab or infliximab for RA

Inpharma, Vol. 1, Iss. 1614, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Etanercept of greater value than adalimumab or infliximab for RA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 541, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Etanercept considered cost effective vs DMARDs in RA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 446, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Etanercept has only minimal cost effect in juvenile RA

Inpharma, Vol. 1, Iss. 1469, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite